Alexander C. Sapir
CEO, President & DirectorMr. Alexander C. Sapir, also known as Alex, serves as Chief Executive Officer, President and Director at Fulcrum Therapeutics, Inc. since July 01, 2023. Mr. Sapir has been Director at PhaseBio Pharmaceuticals, Inc. since February 2020. Mr. Sapir served as Chief Executive Officer and Director at ReViral Ltd. since June 10, 2019 and is Chief Executive Officer and Director since 2025. He was Chief Executive Officer of ReViral Therapeutics. Mr. Sapir served as the Chief Executive Officer and President of Dova Pharmaceuticals, Inc since January 2017 until December 2018 and serves as its Director from March 2017 until April 26, 2019. From January 2006 to May 2016, Mr. Sapir served as Executive Vice President of Marketing and Sales for United Therapeutics Corporation. Prior to his time at United Therapeutics Corporation, from January 2003 to January 2005, Mr. Sapir served as Senior Director of Marketing for Guilford Pharmaceuticals. He began his career at GlaxoSmithKline serving in various commercial roles in the United States and Europe. He has experience in building commercial stage pharmaceutical organizations. Mr. Sapir spent 10 years as executive vice president for United Therapeutics Corporation, three years as a consultant at ZS Associates and seven years in various commercial roles at GlaxoSmithKline. Mr. Sapir is a routine guest lecturer on the topic of pharmaceutical marketing strategy at Duke University's Fuqua School of Business. Mr. Sapir holds a B.A. in Economics from Franklin and Marshall College and an M.B.A. from Harvard Business School.
Positions
- Company NameFulcrum Therapeutics, Inc.Stock CodeFULCPositionCEO, President & DirectorColleagues
- KHKathryn HavilandIndependent Chair of the Board
- AAAlan A. MussoCFO, Treasurer & Principal Accounting Officer
- CGCurtis G. OltmansChief Legal Officer, Head of External Affairs & Corporate Secretary
- BEBradley E. BernsteinFounder
- MRMichael R. GreenFounder
- JAJames Arthur GeraghtyIndependent Director
- KDKatina DortonIndependent Director
- RKRachel K. KingIndependent Director
